Clinical trials: Flu
Influenza
Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
This study will evaluate the safety and immunogenicity of VAX161B [STF2.HA5 H5N1], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
- Trial name
- NCT01560793
- Testing
- VAX161 [STF2.HA5 H5N1]
- Where
- 2 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere
A study to assess whether the Northern Hemisphere 2008/2009 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines
- Trial name
- NCT01303510
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Healthy
Cigarette Smoke and Susceptibility to Influenza Infection
This study will be a descriptive comparison of the effects of live attenuated influenza virus (FluMist) on nasal inflammation and oxidative stress in healthy young adults who are not exposed to smoke vs smokers.
- Trial name
- NCT00448617
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Orthomyxoviridae Infection, Influenza
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
Primary Objective: To evaluate for each influenza strain the non-inferiority of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00391391
- Testing
- Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
- Where
- 19 sites in United States
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.
- Trial name
- NCT03883113
- Testing
- MVA-NP+M1, Saline, H3N2 (A/Belgium/2417/2015)
- Where
- Belgium
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Influenza
Maternal Flu Vaccine Trial in Bamako, Mali
The Center for Vaccine Development - Mali is interested in learning if vaccinating a pregnant woman against influenza will protect her infant against this disease.
- Trial name
- NCT01430689
- Testing
- Inactivated Influenza Vaccine Trivalent Types A and B, Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
- Where
- Mali
- Volunteers
- 4,193 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Influenza
A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months
In this single-center, randomized, blinded, positive-controlled design, the investigators will assess the safety and immunogenicity of 2 doses of an inactivated quadrivalent influenza vaccine in children aged 6 to 35 months.
- Trial name
- NCT05212623
- Testing
- quadrivalent influenza split vaccine, Influenza virus split vaccine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Healthy
Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults
DNA vaccines consist of small pieces of DNA also known as plasmids, and have several potential advantages over traditional vaccines. Thus far, DNA vaccines appear to be well tolerated in humans.
- Trial name
- NCT01142362
- Testing
- VGX-3400X
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Influenza A Subtype H5N1 Infection
H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers
The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of pandemic influenza.
- Trial name
- NCT01657929
- Testing
- H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R)
- Where
- 3 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Influenza Vaccines
A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00586469
- Testing
- Fluviral
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Decreased Immunologic Activity [PE], Influenza
Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients
In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There is no data concerning the immunogenicity nor the security of the adjuvanted-A/H1N1 vaccine in renal disease patients.
- Conditions
- Decreased Immunologic Activity [PE], Influenza, Rejection
- Trial name
- NCT01298102
- Testing
- Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)
- Where
- Belgium
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Influenza, Avian
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents
The purpose of this study is to assess the safety and immunogenicity (i.e. primary immune response, immunogenicity of two different doses, antibody persistence 360 days after the first vaccination, immune response to a…
- Trial name
- NCT01052402
- Testing
- H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
- Where
- 20 sites in Australia, Finland and 2 more
- Volunteers
- 684 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Vaccine Response
Probiotics and Influenza Vaccination Response
Assess efficacy of oral ingestion of a probiotic product on immune function in a population of healthy adult men and women in a clinical vaccination study.
- Trial name
- VERB (NCT05690373)
- Testing
- Probiotic effect on influenza vaccine response
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Healthy Volunteers
A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers
The primary objective of the study is to determine whether titration of Avonex reduces the severity of flu-like symptoms (FLS). Secondary objectives of this study are to determine whether titration of Avonex reduces the incidence…
- Trial name
- NCT01119677
- Testing
- Avonex
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy
A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine
This prospective annual release study was designed to assess the safety of a monovalent influenza virus vaccine using a new strain recommended for the 2009-2010 influenza season not previously contained in the trivalent…
- Trial name
- MI-MA205 (NCT00873912)
- Testing
- Monovalent influenza virus vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over
The goal of this study is to determine whether the immune responses induced by Fluviral, the investigational vaccine, are comparable to those induced by Fluzone, which is an influenza vaccine currently licensed in the U.S.
- Trial name
- NCT00232947
- Testing
- Influenza virus vaccine (Fluviral), Influenza virus vaccine (Fluzone)
- Where
- 10 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- ID Biomedical Corporation, Quebec
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
- Trial name
- NCT01416571
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children
This study is a randomized controlled trial (RCT) comparing adjuvanted influenza vaccine (AV) to unadjuvanted inactivated influenza vaccine (IIV). Children in Hutterite colonies in Alberta and Saskatchewan will receive AV or IIV.
- Trial name
- NCT02871206
- Testing
- Fluad, Fluzone
- Where
- Canada
- Volunteers
- 3,425 people, healthy volunteers welcome
- Sponsor
- McMaster University
Influenza
Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
The purpose of this study is to describe the immune response to a novel H1N1 influenza vaccination in healthy adults, and to understand the factors that allow healthy adults to respond to a single dose of vaccine even if they…
- Trial name
- NCT01023711
- Testing
- Inactivated H1N1 vaccine
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza, Human
Vaccine Pandemic Preparedness Through Airway Immunology Characterization
The study aims to compare the effectiveness of live attenuated influenza vaccines (LAIV) and intramuscular-inactivated vaccines (IIV) in healthy individuals aged 18-49.
- Trial name
- VAXXAIR (NCT05921448)
- Testing
- Vaxigripetra, Flumist
- Where
- 7 sites in Denmark, United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Copenhagen Respiratory Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.